CytoSolve

CytoSolve, Inc. is a US-based corporation, which has created a technology platform for in silico drug discovery and development through quantitative modeling of complex molecular pathways - potentially supplanting the need for animal testing and reducing the time it takes for drugs or nutraceuticals to be brought to market. CytoSolve specializes in the use of its technology platform for discovery of multi-combination compounds for both the prevention and cure of major diseases such as cancer, obesity, inflammation and others.
The company was incorporated as a Delaware Corporation on 7 March 2011.
History
CytoSolve was founded in 2011 by Dr. VA Shiva Ayyadurai, an inventor, systems scientist and MIT-trained systems biologist, following his doctoral research in molecular systems biology at the , department of Biological Engineering, and his field work in eastern and traditional systems of medicine such as Siddha, Ayurveda and Traditional Chinese Medicine. The company was incorporated as a Delaware corporation, with its place of business in Cambridge, Massachusetts.
In 2011, Dr. VA Shiva Ayyadurai provided the initial seed capital for the company. In 2012, the company received its first round of funding from early-stage private investors. Dr. Deepak Chopra, a medical doctor and pioneer in integrative medicine, and founder of the Chopra Center for Well Being, as well as Thomas Zawacki, an Internet pioneer and creator of Lemonade.Com, joined the Board of Directors of CytoSolve in 2013.
Scientific Relevance
CytoSolve’s core technology platform, provides a method for drug development as well as for developing combinatorial drug therapies, has been the basis of scientific study and interest in a number of university research projects.
In 2006, the National Science Foundation issued a grand challenge to create a computational or mathematical model of the whole human cell. In 2007, Dr. VA Shiva Ayaydurai developed a software platform called CytoSolve that provided a computational architecture for whole cell modeling, by providing a mechanism to integrate large-scale molecular pathway models. In 2010, a peer-reviewed journal article entitled "A Scalable Computational Method for Dynamic Integration of Multiple Molecular Pathway Models" was published. In 2011, another paper which described the architecture of the CytoSolve approach for whole cell modeling was published.
In order to model the whole cell, multi-scale modeling is of importance, a critical feature that CytoSolve provides. A scientific paper titled "Combinatorial drug therapy for cancer in the post-genomic era" published in July 2012 issue states that "Computational protocols, such as CytoSolve, allow the combination of alternative models and generation of consensus hypotheses." A scientific paper titled “Setting a Research Agenda for Progressive MS: The International Collaborative on Progressive MS” cited CytoSolve as "… techniques hold promise to provide the tools for interpreting genetic data across different knowledge domains."

Main Menu

See Also

Main Menu